Global Neurological Biomarkers Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
6.92 Billion
USD
21.45 Billion
2022
2030
 Período de previsão |
2023 –2030 |
 Tamanho do mercado (ano base ) | USD 6.92 Billion |
 Tamanho do mercado ( Ano de previsão) | USD 21.45 Billion |
 CAGR |
% |
| Principais participantes do mercado |
|
Global Neurological Biomarkers Market, By Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson's Disease, Schizophrenia, Huntington's Disease, Alzheimer's Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical and Biotechnology Companies, Research Organizations) – Industry Trends and Forecast to 2030.
Neurological Biomarkers Market Analysis and Size
As per the WHO, in 2016, epilepsy accounted for about 13 million disability-adjusted life years and more than 0.5% of the global disease burden. This increasing occurrence of neurological disorders can surge the demand for neurological biomarkers as it will help detect the disease. Furthermore, advanced imaging systems are helping in the early diagnosis of various diseases while decreasing the mortality rate.
Data Bridge Market Research analyses that the neurological biomarkers market, which was USD 6.92 billion in 2022, would rise to USD 21.45 billion by 2030 and is expected to undergo a CAGR of 13.4% during the forecast period from 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Neurological Biomarkers Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson's Disease, Schizophrenia, Huntington's Disease, Alzheimer's Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical and Biotechnology Companies, Research Organizations) |
|
Countries Covered |
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Thermo Fisher Scientific (U.S.), QIAGEN (Netherlands), Agilent Technologies, Inc. (U.S.), McKesson Corporation (U.S), R1 RCM Inc., (U.S), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), BGI (China), Quanterix (U.S.), bioMérieux Inc (U.S.), Neurosteer Inc. (U.S.), Advanced Brain Monitoring, Inc (U.S.) |
|
Market Opportunities |
|
Market Definition
Neurological biomarkers are the biomarkers regarded as criteria for evaluating and calculating a method or symptom for acquiring a pharmacological response to a particular treatment. They are widely used for identifying numerous diseases, such as Parkinson's disease, autism, and depression. The common types of neurological biomarkers are imaging, genomics, proteomics, and metabolomics.
Global Neurological Biomarkers Market Dynamics
Drivers
- Increasing Technological Advancements by Market Players
Recent advancements in biomarkers, such as biomarker signatures, make neurological diseases more treatable. This has resulted in faster drug development, noninvasive testing, and early diagnosis. Additionally, digital biomarkers offer numerous pharmaceutical companies with supplemental information to conclude clinical trial decisions. The National Institute of Neurological Disorders and Stroke provides funding, such as development grants and cooperative agreements, for researchers performing studies associated with biomarker discovery, analytical validation, and clinical validation. Thus, this factor boosts market growth.
- Increasing Development of Precision Medicine
Biomarker research in neurodegenerative disease is a huge advancing area in personalized medicine. Many molecules have been assessed and associated with varied neurodegenerative disorders. This evolution within precision medicine has impacted the biopharmaceutical industry. Different players, from biopharma to diagnostics companies with several functions, such as research and development to commercial operations, will observe a huge change. This is anticipated to impact the market growth positively.
Opportunities
- Increasing Funds by Market Players
The wide presence of organizations providing funds at numerous stages of research is expected to drive market growth. For instance, the University of North Texas Health Science Center (HSC) was awarded about USD 45.5 million in funds from the National Institutes of Health (NIH) to support research associated with health disparities in Alzheimer's and brain aging. NIH is providing additional funds for biomarkers research for the current Health and Aging Brain Among Latino Elders (HABLE) study. Therefore, this factor boosts the market growth.
Restraints/Challenges
- High Startup Costs and Protracted Biomarker Development Cycles
The biomarkers vary in how well they perform in illness detection. Thus assessing biomarkers is a time-consuming process. Consequently, the validation process grows costly and time-consuming. The process and timetable for developing and validating biomarkers are thus comparable across various biomarker categories, with a few exceptions, as varied categories of biomarkers frequently share common development and validation process phases. Thus, this factor impedes market growth.
This neurological biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurological biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2020, Johnson & Johnson Services, Inc. entered into a strategic agreement with Enigma Biomedical Group to assess novel neuroimaging biomarkers-JNJ-64413739 and JNJ-64511070-to understand Alzheimer's disease and other dementias.
Global Neurological Biomarkers Market Scope
The neurological biomarkers market is segmented on the basis of product type, indication, imaging techniques, services, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Genomics Biomarker
- Proteomics Biomarker
- Imaging Biomarker
- Metabolomics Biomarker
- Others
Indication
- Spinal Muscular Atrophy
- Parkinson's Disease
- Schizophrenia
- Huntington's Disease
- Alzheimer's Disease
- Depression
- Multiple Sclerosis
Imaging Techniques
- Transcranial Magnetic Stimulation
- Diffusion Tensor Imaging
- Conventional Structural MRI
- Functional Magnetic Resonance Imaging
- Positron Emission Tomography
Services
- Sample Preparation
- Assay Development
- Biomarker Validation and Testing
End User
- Clinical Diagnostics
- Pharmaceutical And Biotechnology Companies
- Research Organizations
Neurological Biomarkers Market Regional Analysis/Insights
The neurological biomarkers market is analyzed and market size insights and trends are provided by product type, indication, imaging techniques, services and end user as referenced above.
The countries covered in the neurological biomarkers market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the neurological biomarkers market because of the increase in healthcare expenditure and huge commercial performances of neurological diagnostics in the U.S. Furthermore, the growing product launches combined with the increase in demand for biomarkers are anticipated to impact the regional market positively.
Asia-Pacific is expected to witness significant growth because of the region's improvement in healthcare infrastructure and increase in disposable income. Also, an increasing number of clinical trials being performed in emerging countries, such as India and China, leads to market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The neurological biomarkers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for neurological biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the neurological biomarkers market. The data is available for historic period 2011-2021.
Competitive Landscape and Neurological Biomarkers Market Share Analysis
The neurological biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the neurological biomarkers market.
Some of the major players operating in the neurological biomarkers market are:
- Thermo Fisher Scientific (U.S.)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (U.S.)
- McKesson Corporation (U.S)
- R1 RCM Inc., (U.S)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bio-Rad Laboratories, Inc. (U.S.)
- BGI (China), Quanterix (U.S.)
- bioMérieux Inc (U.S.)
- Neurosteer Inc. (U.S.)
- Advanced Brain Monitoring, Inc (U.S.)
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
